Addictions, Drug & Alcohol Institute, University of Washington, Seattle, WA, USA.
Department of Health Systems and Population Health, School of Public Health, University of Washington, Seattle, WA, USA.
Addict Sci Clin Pract. 2022 Jul 7;17(1):34. doi: 10.1186/s13722-022-00315-4.
Opioid use disorder (OUD) is a serious health condition that is effectively treated with buprenorphine. However, only a minority of people with OUD are able to access buprenorphine. Many access points for buprenorphine have high barriers for initiation and retention. Health care and drug treatment systems have not been able to provide services to all-let alone the majority-who need it, and many with OUD report extreme challenges starting and staying on buprenorphine in those care settings. We describe the design and protocol for a study of a rapid access buprenorphine program model in six Washington State communities at existing sites serving people who are unhoused and/or using syringe services programs. This study aimed to test the effectiveness of a Community-Based Medication-First Program model.
We are conducting a hybrid effectiveness-implementation study of a rapid access buprenorphine model of care staffed by prescribers, nurse care managers, and care navigators. The Community-Based Medication-First model of care was designed as a 6-month, induction-stabilization-transition model to be delivered between 2019 and 2022. Effectiveness outcomes will be tested by comparing the intervention group with a comparison group derived from state records of people who had OUD. Construction of the comparison group will align characteristics such as geography, demographics, historical rates of arrests, OUD medication, and health care utilization, using restriction and propensity score techniques. Outcomes will include arrests, emergency and inpatient health care utilization, and mortality rates. Descriptive statistics for buprenorphine utilization patterns during the intervention period will be documented with the prescription drug monitoring program.
Results of this study will help determine the effectiveness of the intervention. Given the serious population-level and individual-level impacts of OUD, it is essential that services be readily available to all people with OUD, including those who cannot readily access care due to their circumstances, capacity, preferences, and related systems barriers.
阿片类药物使用障碍(OUD)是一种严重的健康状况,可以通过丁丙诺啡有效治疗。然而,只有少数 OUD 患者能够获得丁丙诺啡。许多丁丙诺啡的获取途径在启动和保留方面存在很高的障碍。医疗保健和药物治疗系统未能为所有需要服务的人提供服务——更不用说大多数人了,许多 OUD 患者报告说,在这些护理环境中,开始和继续使用丁丙诺啡面临极端挑战。我们描述了一项在华盛顿州六个社区开展的快速获取丁丙诺啡项目模型的研究的设计和方案,该项目模型在为无家可归者和/或使用注射器服务项目的人群提供服务的现有场所开展。这项研究旨在测试一种以社区为基础的药物优先模式的有效性。
我们正在对一个快速获取丁丙诺啡模式的护理进行混合有效性-实施研究,该模式由处方医生、护士护理经理和护理导航员提供服务。以社区为基础的药物优先护理模式被设计为一个为期 6 个月的诱导-稳定-过渡模式,从 2019 年到 2022 年实施。通过将干预组与从有 OUD 的人的州记录中得出的对照组进行比较,来测试有效性结果。对照组的构建将通过限制和倾向评分技术,根据地理位置、人口统计学、历史逮捕率、OUD 药物和医疗保健利用等特征进行匹配。结果将包括逮捕、紧急和住院医疗保健利用以及死亡率。干预期间丁丙诺啡利用模式的描述性统计数据将通过处方药物监测计划记录。
这项研究的结果将有助于确定干预措施的有效性。鉴于 OUD 对人群和个人的严重影响,至关重要的是,所有 OUD 患者都能获得服务,包括那些由于自身情况、能力、偏好和相关系统障碍而难以获得护理的患者。